Macquarie Group
ACHL

Macquarie Group’s Achilles Therapeutics ACHL Stock Holding History

Macquarie Group’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-40,402
Closed -$396K – 2644
2021
Q2 		$396K Sell
40,402
-14,845
-27% -$201K ﹤0.01% 1717
2021
Q1 		$914K Buy
+55,247
New +$914K ﹤0.01% 1417

Other funds holding ACHL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Macquarie Group's ACHL Position: Q3 2021 in Review

Macquarie Group sold out of Achilles Therapeutics (ACHL) in Q3 2021, closing a stake of 40,402 shares — an estimated $396K sold.

Macquarie Group first reported a position in ACHL in Q1 2021 and held it in 2 quarters. The position peaked at $914K in Q1 2021. 20 funds tracked by Wall St. Rank hold ACHL as of Q3 2021.

  • Macquarie Group reported no remaining Achilles Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Macquarie Group sold 40,402 Achilles Therapeutics shares in Q3 2021, an estimated $396K.
  • Macquarie Group first reported a position in Achilles Therapeutics in Q1 2021 and held it in 2 quarters.
  • Macquarie Group's Achilles Therapeutics position peaked at $914K in Q1 2021.
  • 20 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q3 2021.

Based on Macquarie Group's 13F filing for Q3 2021, filed 12 Nov 2021.